GGrantIndex
Sort

30,917 grants matching tumor microenvironment

A pro-metastatic secretory pathway activated by p53 loss in lung cancer

$542,703
Jonathan M Kurie · University Of Tx Md Anderson Can Ctr · R01 · FY2025 · CA

Leveraging Biologically Specific PET/MRI Monitoring and Therapeutic Modulation of the Hypoxic Glioblastoma Tumor Immune Microenvironment into Improved Outcomes

$542,641
Ramon Francisco Barajas · Oregon Health & Science University · R37 · FY2025 · CA

Single Cell Genome-Wide Myeloid Response Profiling in Immunotherapy

$542,592
Allon Moshe Klein · Harvard Medical School · R01 · FY2020 · CA

Project 3: Development of Strategies to Deplete Myelofibrosis Stem Cells

$542,504
Ronald Hoffman · Icahn School Of Medicine At Mount Sinai · P01 · FY2024 · CA

Targeting Novel Pathways in JMML

$542,416
Reuben Kapur · Indiana University Indianapolis · R01 · FY2022 · HL

Targeting Novel Pathways in JMML

$542,416
Reuben Kapur · Indiana University Indianapolis · R01 · FY2021 · HL

Chemokine interaction with CXCR4 and ACKR3: structure and activation mechanisms

$542,393
Tracy M Handel · University Of California, San Diego · R01 · FY2017 · GM

Chemokine interaction with CXCR4 and ACKR3: structure and activation mechanisms

$542,393
Tracy M Handel · University Of California, San Diego · R01 · FY2019 · GM

Small molecule probes of MYC stability and function intumorigenesis

$542,383
Sarki A. Abdulkadir · Northwestern University At Chicago · R01 · FY2024 · CA

Mechanism of Activity of Lonidamine

$542,325
Jerry D Glickson · University Of Pennsylvania · R01 · FY2017 · CA

Mechanism of Activity of Lonidamine

$542,325
Jerry D Glickson · University Of Pennsylvania · R01 · FY2016 · CA

CTCF in CD8 T cell homeostasis and anti-viral/tumor immunity

$542,314
Hai-Hui Xue · Hackensack University Medical Center · R01 · FY2022 · AI

Antigen-Presenting Cell Control of CD8+ T Cell Exhaustion in Cancer

$542,252
Ming Li · Sloan-Kettering Inst Can Research · R01 · FY2025 · CA

Antigen-Presenting Cell Control of CD8+ T Cell Exhaustion in Cancer

$542,252
Ming Li · Sloan-Kettering Inst Can Research · R01 · FY2023 · CA

Artificial, Humanized Stem Cell Niches

$542,171
Biju Parekkadan · Rutgers, The State Univ Of N.J. · R01 · FY2021 · EB

Development of multifunctional drug and immune modulator delivery nanoparticles for the treatment of cancer patients with comorbid atherosclerosis

$542,085
Lily Yang · Emory University · R01 · FY2021 · CA

Manipulating normal estrogen physiology as a therapeutic approach in cancer

$542,002
Donald P McDonnell · Duke University · R01 · FY2025 · CA

Development of a novel therapy targeting the tumor microenvironment in inflammatory breast cancer

$541,958
Naoto T Ueno · University Of Hawaii At Manoa · R01 · FY2024 · CA

DCE MRI Study for Breast Cancer.

$541,897
Sungheon Gene Kim · New York University School Of Medicine · R01 · FY2014 · CA

Elucidating genetics of response to immune checkpoint blockade in lung cancer

$541,884
Naiyer A Rizvi · Columbia University Health Sciences · R01 · FY2019 · CA

Understanding how adrenergic signaling influences immune contexture of tumors and the efficacy of checkpoint inhibitors

$541,844
Elizabeth Repasky · Roswell Park Cancer Institute Corp · R01 · FY2019 · CA

Role of S.aureus in Cutaneous T Cell Lymphoma Pathogenesis

$541,819
Sergei Borisovich Koralov · New York University School Of Medicine · R01 · FY2023 · CA

Innovative Approaches to Treat Duchenne Muscular Dystrophy Using iPSC-Derived Muscle Progenitors

$541,817
Yao Liang Tang · Augusta University · R01 · FY2017 · AR

Tumor-barcoding coupled with high-throughput sequencing for quantitative radiogenomics of the abscopal response in NSCLC

$541,670
Phuoc T. Tran · University Of Maryland Baltimore · R01 · FY2023 · CA

Role of FGFR1 signaling in distinct cell lineages in prostate cancer progresssion

$541,659
Michael M. Ittmann · Baylor College Of Medicine · U01 · FY2013 · CA